+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Market Analysis, Size, Trends | Europe | 2019-2025

  • PDF Icon

    Report

  • July 2019
  • Region: Europe
  • iData Research
  • ID: 4876609

In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international markets.

In the pipeline, Abbott is seeking to launch an update to its FGM platform, extending usage life and implanting other features, such as integration with insulin pumps. FGM is described as a hybrid between blood glucose meters and continuous glucose monitoring (CGM), because it measures interstitial fluid glucose levels through a sensor, but patients must perform manual “scans” by placing a device up to the sensor to view a reading. FGM also eliminates the need for fingersticking, which is a common patient complaint about other glucose monitoring devices. The product was met with outstanding demand when it was first launched, resulting in product shortages in early 2015. Production capability issues have since then been resolved and unit sales have resumed at a growing rate. It is expected that growth will decelerate once a sizable installed base has been established in the European market.

The full report suite on the European market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pen needles, insulin syringes and insulin pumps.


Table of Contents


LIST OF FIGURESLIST OF CHARTS
1. EXECUTIVE SUMMARY
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
2. DISEASE OVERVIEW
2.1 INTRODUCTION
2.1.1 Types of Diabetes
2.1.2 Diabetes Complications
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes
2.1.4 Signs and Symptoms
2.1.5 Diabetes Monitoring
2.1.6 Treatment
2.1.7 Drug Delivery Systems
3. PRODUCT ASSESSMENT
3.1 INTRODUCTION
3.2 PRODUCT PORTFOLIOS
3.2.1 Blood Glucose Meter
3.2.1.1 Personal
3.2.1.2 Professional
3.2.2 Blood Glucose Test Strip
3.2.2.1 Personal
3.2.2.2 Professional
3.2.3 Lancet
3.2.3.1 Personal
3.2.3.2 Professional
3.2.4 Continuous Glucose Monitoring
3.2.4.1 Personal
3.2.4.2 Professional
3.2.5 Flash Glucose Monitoring
3.2.5.1 Sensor
3.2.5.2 Reader
3.2.6 Insulin
3.2.6.1 Insulin Types
3.2.6.1.1 Rapid-Acting Insulin Analog
3.2.6.1.2 Regular Human Insulin
3.2.6.1.3 Intermediate-Acting Human Insulin
3.2.6.1.4 Long-Acting Insulin Analog
3.2.6.1.5 Ultra-Long-Acting Insulin Analog
3.2.6.1.6 Premixed Insulin
3.2.7 Insulin Pen
3.2.7.1 Prefilled Pen
3.2.7.2 Reusable Pen
3.2.8 Insulin Syringe
3.2.8.1 Conventional Insulin Syringe
3.2.8.2 Safety Insulin Syringe
3.2.9 Insulin Pump
3.2.9.1 Durable Insulin Pumps
3.2.9.2 Patch Insulin Pumps
3.2.9.3 Simple Insulin Pumps
3.3 REGULATORY ISSUES AND RECALLS
3.3.1 Becton Dickinson
3.3.1.1 Insulin Syringe
3.3.1.2 Insulin Pump
3.3.2 Dexcom
3.3.2.1 Continuous Glucose Monitoring (CGM)
3.3.3 Insulet
3.3.3.1 Insulin Pump
3.3.4 Medtronic
3.3.4.1 Blood Glucose Meter
3.3.4.2 Continuous Glucose Monitoring (CGM)
3.3.4.3 Insulin Pump
3.3.4.4 Software
3.3.5 Novo Nordisk
3.3.5.1 Insulin Pen
3.3.6 Roche
3.3.6.1 Insulin Pump
3.3.6.2 Test Strip
3.4 CLINICAL TRIALS
3.4.1 Abbott
3.4.1.1 Flash Glucose Meter
3.4.2 Ascensia
3.4.2.1 Glucose Meter
3.4.3 Becton Dickinson
3.4.3.1 Insulin Syringe
3.4.4 Companion Medical, Inc
3.4.4.1 Insulin
3.4.5 Dexcom
3.4.5.1 Continuous Glucose Meter
3.4.6 East Coast Institute for Research & Valeritas, Inc. & Dallas Diabetes Research
3.4.6.1 Insulin
3.4.7 East Tennessee State University &Medtronic
3.4.7.1 Insulin
3.4.8 Eli Lilly
3.4.8.1 Insulin
3.4.9 Emory University
3.4.9.1 Insulin
3.4.10 HealthPartners Institute & National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) & Medtronic & University of Minnesota - Clinical and Translational Science Institute & Jaeb Center for Health
3.4.10.1 Insulin Pump
3.4.11 Insulet
3.4.11.1 Insulin Pump
3.4.12 Jaeb Center for Health Research & National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)& Cambridge University Hospitals NHS Foundation Trust & University of Colorado Denver School of Medicine Barbara Davis Center & Indiana University & The Leeds Teaching Hospitals NHS Trust & Stanford University & Yale University
3.4.12.1 Insulin Pump
3.4.13 Jaeb Center for Health Research & Stanford University & Tidepool Project & RileyLink
3.4.13.1 Insulin Pump
3.4.14 Jaeb Center for Health Research & The Leona M. and Harry B. Helmsley Charitable Trust
3.4.14.1 CGM
3.4.15 Joslin Diabetes Center & Cambridge Medical Technologies, LLC
3.4.15.1 CGM
3.4.16 Joslin Diabetes Center & National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
3.4.16.1 Insulin Pump
3.4.17 Medtronic
3.4.17.1 New Technologies
3.4.18 Methodist Medical Center of Illinois
3.4.18.1 CGM
3.4.19 Novo Nordisk
3.4.19.1 Insulin
3.4.20 Sanofi
3.4.20.1 Insulin
3.4.21 Sansum Diabetes Research Institute & Novo Nordisk A/S
3.4.21.1 Insulin
3.4.22 Senseonics, Inc.
3.4.22.1 CGM
3.4.23 Stanford University
3.4.23.1 Insulin Pump
3.4.24 Stanford University & Medtronic
3.4.24.1 Insulin Pump
3.4.25 University of Colorado, Denver & National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - University of Colorado Denver School of Medicine Barbara Davis Center & Colorado Clinical & Translational Sciences Institute & National Center for Advancing Translational Science (NCATS)
3.4.25.1 Insulin
3.4.26 University of Florida & Diabetes Action Research and Education Foundation
3.4.26.1 CGM
3.4.27 University of Maryland & Baltimore VA Medical Center
3.4.27.1 CGM
3.4.28 University of Miami
3.4.28.1 Insulin
3.4.29 University of Michigan
3.4.29.1 CGM
3.4.30 University of Minnesota - Clinical and Translational Science Institute
3.4.30.1 CGM
3.4.31 University of Virginia & DexCom, Inc.
3.4.31.1 CGM
3.4.32 University of Virginia & Tandem Diabetes Care, Inc. & DexCom, Inc. & Jaeb Center for Health Research
3.4.32.1 CGM
3.4.33 University of Washington - DexCom, Inc.
3.4.33.1 CGM
3.4.34 Virginia Commonwealth University
3.4.34.1 CGM
3.4.35 Yale University
3.4.35.1 Insulin
4. EUROPEAN DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW
4.1 CURRENCY EXCHANGE RATE
4.2 MARKET OVERVIEW
4.3 TREND ANALYSIS BY SEGMENT
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE MARKET SHARE ANALYSIS
4.6 MERGERS AND ACQUISITIONS
4.7 COMPANY PROFILES
4.7.1 Abbott
4.7.2 Ascensia
4.7.3 Becton Dickinson
4.7.4 Dexcom
4.7.5 Eli Lilly
4.7.6 Insulet
4.7.7 LifeScan
4.7.8 Medtronic
4.7.9 Novo Nordisk
4.7.10 Roche
4.7.11 Sanofi
4.8 SWOT ANALYSIS
4.8.1 Abbott
4.8.2 Ascensia
4.8.3 Becton Dickinson
4.8.4 Dexcom
4.8.5 Eli Lilly
4.8.6 Insulet
4.8.7 LifeScan
4.8.8 Medtronic
4.8.9 Novo Nordisk
4.8.10 Roche
4.8.11 Sanofi
5. COUNTRY PROFILES
5.1 INTRODUCTION
5.1.1 Population
5.1.2 GDP Per Capita
5.1.3 Price Index
5.2 GERMANY
5.3 FRANCE
5.4 UNITED KINGDOM
5.5 ITALY
5.6 SPAIN
5.7 BENELUX
5.8 SCANDINAVIA
5.9 AUSTRIA
5.10 SWITZERLAND
5.11 PORTUGAL
6. BLOOD GLUCOSE METER MARKET
6.1 INTRODUCTION
6.2 MARKET ANALYSIS AND FORECAST
6.3 DRIVERS AND LIMITERS
6.3.1 Market Drivers
6.3.2 Market Limiters
6.4 COMPETITIVE MARKET SHARE ANALYSIS
7. BLOOD GLUCOSE TEST STRIP MARKET
7.1 INTRODUCTION
7.2 MARKET ANALYSIS AND FORECAST
7.3 DRIVERS AND LIMITERS
7.3.1 Market Drivers
7.3.2 Market Limiters
7.4 COMPETITIVE MARKET SHARE ANALYSIS
8. LANCET MARKET
8.1 INTRODUCTION
8.2 MARKET ANALYSIS AND FORECAST
8.3 DRIVERS AND LIMITERS
8.3.1 Market Drivers
8.3.2 Market Limiters
8.4 COMPETITIVE MARKET SHARE ANALYSIS
9. CONTINUOUS GLUCOSE MONITORING MARKET
9.1 INTRODUCTION
9.2 MARKET OVERVIEW
9.3 MARKET ANALYSIS AND FORECAST
9.3.1 Continuous Glucose Monitor Receiver Market
9.3.2 Continuous Glucose Monitor Transmitter Market
9.3.3 Continuous Glucose Monitor Sensor Market
9.4 DRIVERS AND LIMITERS
9.4.1 Market Drivers
9.4.2 Market Limiters
9.5 COMPETITIVE MARKET SHARE ANALYSIS
10. FLASH GLUCOSE MONITORING MARKET
10.1 INTRODUCTION
10.2 MARKET OVERVIEW
10.3 MARKET ANALYSIS AND FORECAST
10.3.1 Flash Glucose Monitor Reader Market
10.3.2 Flash Glucose Monitor Sensor Market
10.4 DRIVERS AND LIMITERS
10.4.1 Market Drivers
10.4.2 Market Limiters
10.5 COMPETITIVE MARKET SHARE ANALYSIS
11. INSULIN MARKET
11.1 INTRODUCTION
11.1.1 Insulin Types
11.1.1.1 Rapid-Acting Insulin Analog
11.1.1.2 Regular Human Insulin
11.1.1.3 Intermediate-Acting Human Insulin
11.1.1.4 Long-Acting Insulin Analog
11.1.1.5 Ultra-Long-Acting Insulin Analog
11.1.1.6 Premixed Insulin
11.2 MARKET OVERVIEW
11.3 MARKET ANALYSIS AND FORECAST
11.3.1 Long-Acting Insulin Market
11.3.2 Ultra-Long-Acting Insulin Market
11.3.3 Rapid-Acting Insulin Market
11.3.4 Premixed Insulin Market
11.3.5 Human Insulin Market
11.4 DRIVERS AND LIMITERS
11.4.1 Market Drivers
11.4.2 Market Limiters
11.5 COMPETITIVE MARKET SHARE ANALYSIS
12. INSULIN PEN NEEDLE MARKET
12.1 INTRODUCTION
12.2 MARKET OVERVIEW
12.3 MARKET ANALYSIS AND FORECAST
12.3.1 Conventional Pen Needle Market
12.3.2 Safety Pen Needle Market
12.4 DRIVERS AND LIMITERS
12.4.1 Market Drivers
12.4.2 Market Limiters
12.5 COMPETITIVE MARKET SHARE ANALYSIS
12.5.1 Insulin Pen Needle Market
12.5.2 Conventional Pen Needle Market
13. INSULIN SYRINGE MARKET
13.1 INTRODUCTION
13.2 MARKET ANALYSIS AND FORECAST
13.3 DRIVERS AND LIMITERS
13.3.1 Market Drivers
13.3.2 Market Limiters
13.4 COMPETITIVE MARKET SHARE ANALYSIS
14. INSULIN PUMP MARKET
14.1 INTRODUCTION
14.1.1 Durable Insulin Pumps
14.1.2 Patch Insulin Pumps
14.2 MARKET OVERVIEW
14.3 MARKET ANALYSIS AND FORECAST
14.3.1 Total Durable Insulin Pump Market
14.3.1.1 Durable Pump Market
14.3.1.2 Infusion Set Market
14.3.1.3 Pump Reservoir Market
14.3.2 Total Patch Insulin Pump Market
14.3.2.1 Patch Pump System Market
14.3.2.2 Insulin Pod Market
14.4 DRIVERS AND LIMITERS
14.4.1 Market Drivers
14.4.2 Market Limiters
14.5 COMPETITIVE MARKET SHARE ANALYSIS
14.5.1 Insulin Pump Market
14.5.2 Durable Insulin Pump Market

ABBREVIATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott
  • Medtronic
  • AgaMatrix
  • Menarini
  • Artsana
  • Mendor
  • Ascensia
  • MyGlucoHealth
  • B. Braun
  • NeedleBay
  • Becton Dickinson
  • Neon Diagnostics
  • Cambridge Sensors
  • Nipro
  • DarioHealth
  • Novo Nordisk
  • Dexcom
  • Owen Mumford
  • Eli